Matt McEnany
Biographic Data
| ID | 10158794 |
|---|---|
| NAME | Matt McEnany |
| GIVEN NAMES | Matt |
| FAMILY NAME | McEnany |
| SIGNATURE | MCENANY M |
| AFFILIATIONS | University of Colorado Anschutz Medical Campus |
| ORCID | 0009-0004-9018-011X |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Changes in revenues associated with antimicrobial reimbursement reforms in Germany
Policy declarations from the G7 and other high-level meetings call for increased incentives for antimicrobial research and development (R&D). Governments fund push incentives like CARB-X and GARDP, and G7 countries are now designing pull incentives—financial rewards given to manufacturers post-market authorization that are intended to encourage the creation and introduction of novel antimicrobials. Germany has declared previously at the G7 that i…
No prominent works on this page.
Changes in revenues associated with antimicrobial reimbursement reforms in Germany
Policy declarations from the G7 and other high-level meetings call for increased incentives for antimicrobial research and development (R&D). Governments fund push incentives like CARB-X and GARDP, and G7 countries are now designing pull incentives—financial rewards given to manufacturers post-market authorization that are intended to encourage the creation and introduction of novel antimicrobials. Germany has declared previously at the G7 that i…
Accounting (1 work) · Antibiotic Use and Resistance (1 work) · Antimicrobial (1 work) · Business (1 work) · Chemistry (1 work) · Complementary and Alternative Medicine Studies (1 work) · Economic growth (1 work) · Economics (1 work) · Health care (1 work) · Reimbursement (1 work)